Gunnar Schmidt

Gene panel testing of 5589 <i><scp>BRCA</scp>1/2</i>‐negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer

Jan Hauke, Judit Horváth, Eva Groß et al. · Cancer Medicine · 2018 · 168 citations · Full text

Life Sciences, Genetics, Oncology +17

BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer

Nana Weber‐Lassalle, Jan Hauke, Juliane Ramser et al. · Breast Cancer Research · 2018 · 132 citations · Full text

Medicine, Genetics, Oncology +17

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 Variant Curation Expert Panel

Michael T. Parsons, Miguel de la Hoya, Marcy E. Richardson et al. · The American Journal of Human Genetics · 2024 · 90 citations · Full text

Life Sciences, Genetics, Molecular Genetics +13

The identification of pathogenic variants in <i>BRCA1/2</i> negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of <i>FANCM</i> pathogenic variants

Stephanie Schubert, Jana Lisa van Luttikhuizen, Bernd Auber et al. · International Journal of Cancer · 2018 · 87 citations · Full text

Life Sciences, Genetics, Oncology +17